IP Library Granted Patent US 10,544,211
Granted Patent B2
US 10,544,211 · App. 15/501,011 · Granted Jan 28, 2020

TNF binders

Inventors: Marie-Ange Buyse (Merelbeke, BE); Joachim Boucneau (De Pinte, BE); Peter Casteels (Erpe-Mere, BE); Gino Van Heeke (Eine, BE)
Assignee: Ablynx N.V.
C07K16/241C07K2317/14C07K2317/24C07K2317/565C07K2317/569C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,544,211
App. No.
15/501,011
Granted
Jan 28, 2020
Kind
B2
Abstract

The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.

Claims (18)

1. An immunoglobulin single variable domain (ISVD), comprising:

a CDR1 (according to Abm) that is the amino acid sequence GFTFSTADMG (SEQ ID NO: 5); and

a CDR2 (according to Abm) that is the amino acid sequence RISGIDGTTY (SEQ ID NO: 6); and

a CDR3 (according to Abm) that is the amino acid sequence PRYADQWSAYDY (SEQ ID NO: 4),

wherein the ISVD specifically binds to tumor necrosis factor; and

wherein the ISVD does not comprise the amino acid sequence of SEQ ID NO: 40.

2. An immunoglobulin single variable domain (ISVD), comprising

a CDR1 (according to Abm) that is the amino acid sequence GFTFSTADMG (SEQ ID NO: 5); and

a CDR2 (according to Abm) that is the amino acid sequence RISGIDGTTY (SEQ ID NO: 6); and

a CDR3 (according to Abm) that is the amino acid sequence PRYADQWSAYDY (SEQ ID NO: 4),

wherein the amino acid residue at position 49 is an alanine,

wherein the amino acid residue at position 74 is serine,

wherein the amino acid residue at position 73 is N and the amino acid residue at position 75 is K,

wherein the positions are determined according to Kabat numbering,

wherein the ISVD specifically binds to tumor necrosis factor, and

wherein the ISVD does not comprise the amino acid sequence of SEQ ID NO: 40.

3. An immunoglobulin single variable domain, comprising the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 36.

4. An immunoglobulin single variable domain, consisting of the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 36.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2022
From: ABLYNX N.V.
To: SANOFI
Reel/Frame 059883/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2017
From: BUYSE, MARIE-ANGE; BOUCNEAU, JOACHIM; CASTEELS, PETER; VAN HEEKE, GINO
To: ABLYNX N.V.
Reel/Frame 042993/0852 →
Continuity (2)
Provisional Application 62254375 · Nov 12, 2015
Related Publication 20170267752A1 · Sep 21, 2017
Cited By (4)
US 50,682 US 12,516,105 US 12,630,609 US 12,662,525